Pleiotropic effects of a synthetic analogue of melatonin in the complex therapy of comorbid pathology with a combination of obesity, hypertension and irritable bowel syndrome with constipation

Abstract

In recent years, the role of melatonin and its synthetic analogues in the correction of various pathogenetic mechanisms of disease development has been studied in both experimental and clinical studies. Melatonin receptors are identified in the central and peripheral nervous system, in vascular cells, in the organs of the gastrointestinal tract, it is involved in the regulation of blood pressure, lipid metabolism, autonomic regulation, affects pain. Therefore, the question of the feasibility and effectiveness of involving melatonin drugs in the treatment of various diseases and their comorbidity remains relevant. The aim of the study was to determine the additional pleiotropic effects of a synthetic analogue of melatonin (vita-melatonin) in comorbid pathology in the form of a combination of varying degrees of obesity, hypertension and irritable bowel syndrome with constipation. Results. It was found that the addition to the standard therapy of comorbid patients synthetic analogue of melatonin contributes to a more pronounced reduction in dizziness, pain in the lateral flanks of the abdomen, increased stool frequency, more pronounced reduction in mean systolic and diastolic blood pressure. Other pleiotropic effects of SAM include improved eating behavior, lipid profile, the likelihood of lowering total cholesterol, LDL, acyl triglycerides, and an increase in HDL. Under the influence of the SAM course, the spectral power (TP) increased more markedly, the SDNN index increased, the duration of R-R intervals increased, and the LF complex decreased and HF increased. Also, all patients
who received SAM improved sleep quality, decreased daytime sleepiness and the number of sleep apnea episodes than patients who received standard therapy. Thus, we obtained additional data on the pleiotropic effects of a synthetic analogue of melatonin in patients with comorbidity of obesity, hypertension and irritable bowel syndrome with constipation allows to recommend its inclusion in standard therapy, especially in violation of their eating behavior heart rate and quality and duration of sleep.